Monitoring chromogranine A (CgA) serum levels during chemotherapy for hormone refractory prostate cancer (HRPC): Which impact in daily practice?

16107 Background: Studies published in the literature on CgA serum levels suggest a possible role in the management of patients with HRPC. Methods: Data from 100 patients treated for HRPC with chemotherapy in our institution from 2002 to 2007 were retrospectively analysed. CgA serum level, clinical and biological parameters [Gleason score, performance status (PS), neuron specific enolase (NSE), prostate-specific antigen (PSA), lactate dehydrogenase (LDH), alkaline phosphatase (PAL), albumin (ALB) and hemoglobin (Hb) serum levels,] and clinical outcomes were collected. Baseline parameters (CgA and others) and their variations during chemotherapy were studied. Cox proportional hazards regression models were used for univariate and multivariate analyses. Results: Median age was 69 at time of chemotherapy. Median follow-up was 13.9 months [range, 1.7 to 53.9]. Gleason score was ≥ 7 in 86% of patients, and 47% of patients had metastases at diagnosis. The median baseline serum levels of CgA, PSA and NSE were re...